UnknownNot Applicable

Omega 3 in LES and APS

Brazil22 participantsStarted 2014-05

Plain-language summary

It has been demonstrated that EPA and DHA supplementation may have anti-inflammatory properties in several chronic diseases, namely, diabetes, obesity, and in rheumatoid arthritis, although not with controversy. Systemic lupus erythematosus (SLE) and Antiphospholipid Antibody Syndrome (AAS) are autoimmune diseases characterized by a chronic inflammatory state which is associated with the disease´s clinical symptoms. Thus, we hypothesized that EPA and DHA supplementation may beneficially affect the inflammatory cytokine profile and clinical features of LES and AAS patients.

Who can participate

Age range20 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: • Age between 7 and 40 years Exclusion Criteria: * Cardiovascular dysfunction * Rhythm and conduction disorders * Musculoskeletal disturbances * Kidney and pulmonary involvements * Peripheral neuropathy * Use of tobacco * Treatment with lipid-lowering or hypoglycemic drugs * Fibromyalgia * Use of chronotropic or antihypertensive drugs * Physically active subjects

What they're measuring

Cytokine profile (serum levels of IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-alpha, IFN-y)

Timeframe: 4 months

Endothelial function

Timeframe: 4 months

Trial details

NCT IDNCT01956188

SponsorUniversity of Sao Paulo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-07

View on ClinicalTrials.gov More Systemic Lupus Erythematosus trials